Source link : https://www.newshealth.biz/health-news/isatuximab-approved-first-line-for-transplant-ineligible-mm/
The Food and Drug Administration expanded the label of isatuximab-irfc (Sarclisa — Sanofi-Aventis) on September 20 to include treatment with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma (MM) ineligible for autologous stem cell transplant. The new first-line indication joins two previous approvals of the CD38 antibody for later-line indications, one for relapsed disease […]
Author : News Health
Publish date : 2024-09-23 07:25:48
Copyright for syndicated content belongs to the linked Source.
Categories